Skip to content

Clinical Outcomes From Patient Self-management of Antivitamin K Treatment

Retrospective Analysis of the Clinical Outcomes From Patient Self-management of Antivitamin K Treatment at the Hospitald de Sant Pau. ORION Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03532724
Acronym
ORION
Enrollment
927
Registered
2018-05-22
Start date
2017-11-01
Completion date
2018-09-30
Last updated
2019-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Self Management of Oral Anticoagulation With VKA Therapy

Keywords

Patient Self-management, Acenocoumarol, Warfarin

Brief summary

ORION is a retrospective, observational, one center study to evaluate the incidence of complications (both thromboembolic and bleedings) in a cohort of patients receiving Vitamin K antagonists (VKA) under a self-management program, since 2002 at the Hospital de la Santa Creu i Sant Pau in Barcelona (Spain)

Interventions

DEVICEPatient Self-Management of VKA therapy

Trained patients check weekly the INR using a portable coagulometer an decide by themselves the dosis of VKA

Sponsors

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Adult patients (older than 18) under chronic VKA treatment, whom performed patient self-management for any indication of oral anticoagulation. 2. Signed informed consent

Exclusion criteria

1\. Patients younger than 18 years old

Design outcomes

Primary

MeasureTime frameDescription
Thromboembolic eventssince 1 of july of 2002 to 30th of june of 2018Any documented embolic stroke, peripheral arterial embolism or venous thromboembolism
Major hemorrhagic eventsince 1 of july of 2002 to 30th of june of 2018Any documented bleeding event grade 3 or 5 in the Bleeding Assessment Research Consortium (BARC) scale

Secondary

MeasureTime frameDescription
Mortalitysince 1 of july of 2002 to 30th of june of 2018Death from any cause

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026